Cingulate Inc. (NASDAQ: CING) lifts cash to $28.4M as CTx-1301 faces FDA CMC setback
Rhea-AI Filing Summary
Cingulate Inc. reported second quarter 2026 results and detailed progress on its lead ADHD candidate CTx-1301 and commercialization plans. Cash and cash equivalents were $28.4 million as of June 30 2026, up from $11.0 million at year-end 2025, driven by a $12.0 million private placement and $19.0 million raised via an at-the-market program and a purchase agreement, partially offset by $12.8 million of operating cash use. Working capital rose to $21.6 million, and the company believes this cash will fund operations into mid-2027.
R&D expenses fell to $1.5 million for the quarter, down 44.9% year over year, while SG&A expenses increased to $3.9 million, up 101.5%, reflecting commercial readiness investments. Net loss was $5.9 million for the quarter and $15.2 million for the first half of 2026. Total stockholders’ equity increased to $23.5 million.
Regulatory efforts continue after an FDA Complete Response Letter on June 1 2026 requesting additional CMC information for the CTx-1301 NDA, with no new clinical safety or efficacy concerns cited. Cingulate plans to resubmit the NDA as promptly as practicable, has secured a new U.S. patent protecting CTx-1301 through December 2042, and expanded launch infrastructure through agreements with Prasco, Indegene, and IQVIA.
Positive
- Cash strengthened to $28.4 million at June 30 2026 from $11.0 million at year-end 2025, supported by a $12.0 million private placement and $19.0 million raised via capital agreements, extending expected cash runway into mid-2027.
- The U.S. Patent and Trademark Office issued U.S. Patent No. 12,653,791 covering CTx-1301, providing composition-of-matter and method-of-treatment protection through December 2042 and strengthening the intellectual property position.
- A June 1 2026 FDA Complete Response Letter for CTx-1301 requested additional CMC information only and did not identify concerns regarding clinical safety or efficacy, preserving the clinical risk profile for the lead asset.
Negative
- Second quarter 2026 net loss increased to $5.9 million from $5.0 million a year earlier, and first-half 2026 net loss rose to $15.2 million from $8.8 million, reflecting higher operating expenses.
- Selling, general and administrative expenses more than doubled, rising 101.5% year over year to $3.9 million for the quarter and 181.7% to $9.7 million for the first half, driven by commercialization build-out.
- The FDA issued a Complete Response Letter for the CTx-1301 NDA on June 1 2026, delaying potential approval and requiring additional CMC work, with no assurance regarding the timing of resubmission or approval.
Insights
Analyzing...
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Cash and cash equivalents: $28,402,819
Working capital: $21,577,149
Net loss Q2 2026: $5,870,264
+5 more
8 metrics
Cash and cash equivalents
$28,402,819
As of June 30, 2026
Working capital
$21,577,149
As of June 30, 2026; up from $1,695,633 at December 31, 2025
Net loss Q2 2026
$5,870,264
Three months ended June 30, 2026; vs. $5,0 983,261 in 2025
Net loss H1 2026
$15,182,353
Six months ended June 30, 2026; vs. $8,835,939 in 2025
R&D expense Q2 2026
$1,486,825
Three months ended June 30, 2026; 44.9% decrease year over year
SG&A expense Q2 2026
$3,928,150
Three months ended June 30, 2026; 101.5% increase year over year
Patent term for CTx-1301
December 2042
U.S. Patent No. 12,653,791 protects formulation and use
Capital raised H1 2026
$31,000,000
$12.0M private placement and $19.0M via ATM and purchase agreement
Key Terms
Complete Response Letter, Precision Timed Release, 505(b)(2) pathway, At-the-Market Agreement, +2 more
6 terms
Complete Response Letter regulatory
"follows a Complete Response Letter issued by the FDA on June 1, 2026"
A complete response letter is an official communication from a drug or medical-device regulator, such as the U.S. Food and Drug Administration (FDA), telling a company that a marketing application cannot be approved in its current form and listing the specific deficiencies to be fixed. For investors it matters because it pauses or delays a product’s path to market—like a building inspector issuing a list of repairs before a certificate of occupancy—affecting revenue timing, costs and stock value.
Precision Timed Release technical
"utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform"
A precision timed release is a drug formulation designed so the active ingredient becomes available at specific, predetermined times after a patient takes a dose, rather than all at once. Like a timed sprinkler that waters different zones on schedule, it can improve how well a medicine works, reduce side effects, and make dosing more convenient—factors that affect regulatory approval, patent protection, market differentiation and ultimately a product’s commercial value for investors.
505(b)(2) pathway regulatory
"CTx-1301 is being evaluated for the treatment of ADHD under the FDA’s 505(b)(2) pathway"
A 505(b)(2) pathway is a U.S. regulatory route that lets a drug developer get approval by relying in part on existing clinical data or published studies instead of repeating every test. Think of it as building on someone else’s homework to shorten development time and cost. For investors, it signals potentially faster, lower‑risk market entry and a chance for competitive protection compared with starting brand‑new drug approvals.
At-the-Market Agreement financial
"capital raised on Cingulate’s At-the-Market Agreement with AGP and Purchase Agreement"
An at-the-market agreement is a standing arrangement that lets a company sell newly issued shares directly into the open market through a broker at prevailing market prices, rather than in a single large offering. Like putting a tap on supply that can be turned on gradually, it matters to investors because it provides flexible access to cash and can increase the number of shares available to trade, which may affect share supply and market liquidity.
working capital financial
"Cingulate had approximately $21.6 million in working capital as of June 30, 2026"
Working capital is the money a business has available to cover its daily expenses, like paying bills and buying supplies. It’s like the cash in your wallet that helps you handle everyday costs; having enough ensures the business can operate smoothly without running into money shortages.
PDUFA target action date regulatory
"assigned a PDUFA target action date of May 31, 2026"
The PDUFA target action date is the deadline set by the U.S. Food and Drug Administration (FDA) by which it aims to decide whether to approve or reject a new drug application. This date helps investors gauge when a company’s new medication might reach the market, potentially influencing sales and revenue expectations. It acts as a key milestone signaling progress in the drug approval process.
Earnings Snapshot
Net loss (Q2 2026): $5,870,264 · Guidance included
Quarter and six months ended June 30, 2026
Net loss (Q2 2026)
$5,870,264
Increased from $4,983,261 for Q2 2025
Net loss (H1 2026)
$15,182,353
Increased from $8,835,939 for H1 2025
R&D expense (Q2 2026)
$1,486,825
Decreased 44.9% from $2,700,939 for Q2 2025
SG&A expense (Q2 2026)
$3,928,150
Increased 101.5% from $1,949,035 for Q2 2025
Cash and cash equivalents
$28,402,819
Up from $10,953,383 at December 31, 2025
Guidance
The company believes its cash and cash equivalents will be sufficient to fund operations into mid-2027 under its current business plan.
FAQ
What cash position did Cingulate (CING) report as of June 30, 2026?
Cingulate reported $28.4 million in cash and cash equivalents as of June 30 2026, up from $11.0 million at December 31 2025, and believes this will fund operations into mid-2027 under its current business plan.
How did Cingulate (CING) fund its operations in the first half of 2026?
Cingulate raised $12.0 million in a private placement and $19.0 million through an At-the-Market Agreement and a purchase agreement, partially offset by $12.8 million of cash used for operations, strengthening its working capital position.
What were Cingulate (CING)'s R&D and SG&A expenses for Q2 2026?
For the quarter ended June 30 2026, Cingulate’s R&D expenses were $1.5 million, down 44.9% year over year, while SG&A expenses were $3.9 million, up 101.5%, reflecting lower clinical costs and higher commercialization spending.
What net loss did Cingulate (CING) report for Q2 and the first half of 2026?
Cingulate reported a net loss of $5.9 million for the three months ended June 30 2026 and a net loss of $15.2 million for the six months ended June 30 2026, compared with $5.0 million and $8.8 million in the prior-year periods.
What is the regulatory status of CTx-1301 for Cingulate (CING)?
CTx-1301’s NDA, accepted in October 2025 with a PDUFA date of May 31 2026, received an FDA Complete Response Letter on June 1 2026 requesting additional CMC information; Cingulate plans to resubmit as promptly as practicable but cannot assure timing or approval.
What new patent protection did Cingulate (CING) obtain for CTx-1301?
On June 16 2026, the USPTO issued U.S. Patent No. 12,653,791 titled “Trimodal, Precision-Timed Pulsatile Release Tablet,” providing composition-of-matter, formulation, structural and method-of-treatment protection for CTx-1301 through December 2042.
AI-generated analysis. How Rhea-AI works. Not financial advice.
